

November 25, 2025

Kidswell Bio Corporation (TSE:4584)

S-Quatre Corporation

**Confirming Alignment on the Cerebral Palsy Clinical Trial Plan at the Pre-IND Meeting with U.S. FDA
— SQ-SHED’s Overseas Development Makes Major Strides —**

Tokyo, November 25, 2025 – S-Quatre Corporation, a subsidiary of Kidswell Bio Group, is engaged in the research and development of novel cell-based therapies (regenerative medicine products) using stem cells from human exfoliated deciduous teeth (SHED), with the aim of developing new treatments for pediatric and rare diseases for which no effective therapies currently exist.

S-Quatre has recently held a pre-IND meeting* with the U.S. Food and Drug Administration (FDA) regarding its planned company-sponsored clinical trial of allogeneic SQ-SHED, S-Quatre’s proprietary stem cell, for cerebral palsy. In the meeting, FDA indicated overall alignment with the key elements required for S-Quatre to proceed toward an Investigational New Drug (IND) application and provided constructive guidance.

While the clinical development for pediatric cerebral palsy in Japan is being conducted in collaboration with Mochida Pharmaceutical Co., Ltd., S-Quatre is advancing overseas development under its sole initiative. The pre-IND meeting represents one of the most important milestones in this effort.

The Kidswell Bio Group remains committed to advancing our research and development initiatives with the goal of delivering innovative therapies to patients and families around the world living with cerebral palsy and other intractable diseases.

* pre-IND meeting: A formal meeting in which the FDA is consulted at the early development stage to discuss and confirm the scientific validity of the manufacturing and quality control of the investigational drug, the preclinical studies, and the clinical trial design.

Disclaimer: This English translation is provided for reference purposes only. Should any discrepancies arise between this translation and the original Japanese document, the original Japanese document shall take precedence.